A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study
Damiano Baroncini, Angelo Ghezzi, S. Baldini(Associazione Italiana Sclerosi Multipla), G. Minonzio(Azienda Ospedaliera Sant’Antonio Abate di Gallarate), Antonio Bianchi(University of Catania), Pietro Annovazzi(Vita-Salute San Raffaele University), Giancarlo Comi(University of Milan), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 8
Related Papers
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1
|Nature Neuroscience|2002|446
Multiple sclerosis in childhood: clinical features of 149 cases
|Multiple Sclerosis Journal|1997|309
Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica
|Journal of Neurology|2004|268